The first FDA-approved therapeutic antibody produced based on this technique was adalimumab (Humira), that was approved as an anti-tumor necrosis factor α (TNFα) human antibody against rheumatoid arthritis (RA) in the US in 2002 (86, 132). The gene discussed is TNF; the disease is rheumatoid arthritis.